Bone Marrow Transplant
The Bone Marrow Transplant and Hematologic Malignancies Program at UT Southwestern Medical Center performs autologous (using one’s own cells) and allogeneic (using donor cells) bone-marrow transplants and all additional therapies that support these procedures.
Through state-of-the-art facilities and highly experienced personnel, our program has established an exceptional track record in carrying out these complicated procedures.
Many times, bone marrow transplants are used in conjunction with other therapies to treat patients with certain cancers of the blood, bone marrow, and lymph nodes. Bone marrow transplants can also be used to help patients with certain kinds of blood or immune disorders.
Bone marrow transplants, as well as blood transplants, are also called stem cell transplants. These are transplants of normal mature stem cells from adults.
In certain therapies, patients receive high doses of chemotherapy, and sometimes radiation. These high doses can lead to better control or even cure of the cancers. However, the main side effect of the high doses of chemotherapy is prolonged suppression of the body’s ability to make blood.
To get around this side effect, the patient receives an infusion of hematopoietic stem cells, which make new blood cells and immune cells. They can be obtained either from the bone marrow (bone marrow transplant) or from the blood stream (blood or peripheral blood stem cell transplant).
The Bone Marrow Transplant and Hematologic Malignancies Program provides state-of-the-art care, and includes:
- Accreditation granted by the Foundation for the Accreditation of Cellular Therapy (FACT), which accredits bone marrow transplant programs that have achieved the highest levels of clinical and research practices
- A highly experienced team of physicians, nurses, and ancillary staff
- A hematopathology laboratory that is a recognized world leader in expert diagnosis
- All treatment approaches, including chemotherapy, radiation, stem cell transplantation, immunotherapy, radioimmunotherapy, and experimental therapy
- Excellent clinical results with outcomes superior to national norms in several areas
- Recognized leadership in laboratory and clinical research
Our clinical trials program gives patients access to treatments often unavailable at other health care facilities. Depending on the specific condition, UT Southwestern can offer patients therapies that show particular promise years before those therapies are offered to the public, such as a new method of bone marrow transplantation that de-emphasizes the toxic effects of high-dose chemotherapy and radiation therapy. This therapy emphasizes the powerful anti-cancer effects of donor immune cells, resulting in complete and ongoing remissions in many patients with otherwise incurable malignancies.
Our experience in conducting some of the most advanced research into bone marrow transplants enables UT Southwestern to provide our patients with the best possible medical treatments – all in a caring and compassionate environment.
IDH1 Inhibitor Trial
A phase 1, multi-center, open-label, dose-escalation, safety, pharmacokinetic, pharmacodynamic, and clinical activity study of orally administered AG-120 in subjects with advanced hematologic malignancies with an IDH1 mutation.
In about 20 percent of acute myeloid leukemia (AML) patients, mutations forms of the IDH enzyme cause overproduction of a substance called 2-hydroxyglutarate (2-HG). When too much 2-HG is produced, researchers believe it causes leukemia cells to grow. AG120 inhibits this from happening.
The purpose of this study is to determine the safest effective dose of the drug AG120 that can be given to patients whose AML has returned despite prior therapy or is not responding to standard therapy.
IDH2 Inhibitor Trial
A phase 1, multi-center, open-label, dose-escalation, safety, pharmacokinetic, pharmacodynamic, and clinical activity study of orally administered AG-221 in subjects with advanced hematologic malignancies with an IDH2 mutation.
In about 20 percent of acute myeloid leukemia (AML) patients, mutations of the IDH enzyme cause the overproduction of a substance called 2-hydroxyglutarate (2-HG). When too much 2-HG is produced, researchers believe it causes leukemia cells to grow, and AG221 inhibits this. Researchers believe that AG221 has fewer side effects and is more effective in tackling AML.
The purpose of this study is to find the safest effective dose of AG221 that can be given in patients with AML or myelodysplastic syndromes (MDS).